Unity Biotechnology (UBX) Competitors

Unity Biotechnology (NASDAQ:UBX) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, community ranking, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Do institutionals & insiders have more ownership in UBX or INZY?

29.5% of Unity Biotechnology shares are held by institutional investors. Comparatively, 88.3% of Inozyme Pharma shares are held by institutional investors. 5.8% of Unity Biotechnology shares are held by company insiders. Comparatively, 11.2% of Inozyme Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Which has preferable valuation and earnings, UBX or INZY?

Unity Biotechnology has higher revenue and earnings than Inozyme Pharma. Inozyme Pharma is trading at a lower price-to-earnings ratio than Unity Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unity Biotechnology	$240K	81.40	-$39.86M	-$1.62	-0.70
Inozyme Pharma	N/A	N/A	-$71.17M	-$1.63	-0.78

Do analysts rate UBX or INZY?

Unity Biotechnology presently has a consensus price target of $5.33, indicating a potential upside of 369.90%. Inozyme Pharma has a consensus price target of $14.63, indicating a potential upside of 1,047.06%. Given Inozyme Pharma's higher possible upside, analysts plainly believe Inozyme Pharma is more favorable than Unity Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unity Biotechnology	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Inozyme Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor UBX or INZY?

In the previous week, Unity Biotechnology had 7 more articles in the media than Inozyme Pharma. MarketBeat recorded 11 mentions for Unity Biotechnology and 4 mentions for Inozyme Pharma. Inozyme Pharma's average media sentiment score of 1.28 beat Unity Biotechnology's score of 0.14 indicating that Inozyme Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unity Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Inozyme Pharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in UBX or INZY?

Unity Biotechnology received 120 more outperform votes than Inozyme Pharma when rated by MarketBeat users. However, 88.57% of users gave Inozyme Pharma an outperform vote while only 67.41% of users gave Unity Biotechnology an outperform vote.

Company	Underperform	Outperform
Unity Biotechnology	Outperform Votes 182 67.41%	Underperform Votes 88 32.59%
Inozyme Pharma	Outperform Votes 62 88.57%	Underperform Votes 8 11.43%

Is UBX or INZY more profitable?

Inozyme Pharma's return on equity of -88.42% beat Unity Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unity Biotechnology	N/A	-119.70%	-45.86%
Inozyme Pharma	N/A	-88.42%	-57.02%

Which has more volatility and risk, UBX or INZY?

Unity Biotechnology has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Summary

Inozyme Pharma beats Unity Biotechnology on 9 of the 15 factors compared between the two stocks.